Pancreatic Neoplasms Clinical Trial
Official title:
Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic
We believe that laparoscopic distal pancreatectomy for cancer allows quicker recovery and significantly reduces the chances of postoperative wound breakdown. This will shorten the wait time required to begin adjuvant therapy to one week after surgery thereby combating the micrometastasis unseen at the time of surgery. Prognosis for patients with pancreatic cancer will therefore improve along with decreasing the incidence of locoregional recurrence.
Gemcitabine-based chemo¬therapy remains the cornerstone for treatment of locally advanced or
metastatic pancreatic cancer. Other novel chemotherapeutic combinations have been
investigated in clinical trials, but the overall conclusions are that these agents have
failed to improve outcomes. Our hypothesis is that nodal and hematologic micrometastasis
make pancreas cancer a systemic problem at the time of surgery. Waiting the traditional six
weeks to begin adjuvant therapy allows this very aggressive cancer to metastasize while the
patient is waiting to begin therapy. This leads to the increased incidence of locoregional
recurrence and poor prognosis. We believe that laparoscopic distal pancreatectomy for cancer
allows quicker recovery and significantly reduces the chances of postoperative wound
breakdown. This will shorten the wait time required to begin adjuvant therapy to one week
after surgery thereby combating the micrometastasis unseen at the time of surgery. Prognosis
for patients with pancreatic cancer will therefore improve along with decreasing the
incidence of locoregional recurrence.
Methods: We will perform a prospective, non-randomized phase II study with patients
undergoing laparoscopic distal pancreatectomy for pancreatic adenocarcinoma at Johns Hopkins
Hospital. Gemcitabine will be given as a single-agent chemotherapy regimen one week
following laparoscopic distal pancreatectomy according to the protocol designed by our
medical oncologist. Six cycles of gemcitabine will be given. The patients will be followed
in the medical oncology clinic weekly. Our Primary outcome variable will be all cause
postoperative morbidity. Our sample size will be small (6-10 patients) as this is a Phase II
study. Early termination rules include development of prohibitive toxicity or death. Our
endpoints are an improvement in overall survival, quality of life, progression free
survival, or disease free survival. Exclusion criteria will include patients with T4 or M1
disease, R2 resection margin, preoperative therapy, or if adjuvant therapy status was
unknown.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04085055 -
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
|
N/A | |
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
| Recruiting |
NCT05481476 -
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
| Completed |
NCT02909530 -
Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses
|
N/A | |
| Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
| Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT01515046 -
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
| Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
| Completed |
NCT00985777 -
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
|
Phase 1 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00178763 -
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
|
Phase 2 | |
| Completed |
NCT00136669 -
Acupuncture For Pancreatic Cancer Pain
|
Phase 3 |